DelveInsight’s, “Pulmonary Arterial Hypertension Pipeline Insight, 2023,” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Pulmonary Arterial Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Pulmonary Arterial Hypertension Emerging drugs, the Pulmonary Arterial Hypertension pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Pulmonary Arterial Hypertension pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Pulmonary Arterial Hypertension Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Pulmonary Arterial Hypertension clinical trials studies, Pulmonary Arterial Hypertension NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Pulmonary Arterial Hypertension Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Pulmonary Arterial Hypertension Pipeline landscape @ Pulmonary Arterial Hypertension Pipeline Outlook Report
Pulmonary Arterial Hypertension Overview
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels. The tests that are commonly performed to diagnose PAH and rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test”, which measures how far an individual can walk in that time period.
Recent Developmental Activities in the Pulmonary Arterial Hypertension Treatment Landscape
For further information, refer to the detailed Pulmonary Arterial Hypertension Drugs Launch, Pulmonary Arterial Hypertension Developmental Activities, and Pulmonary Arterial Hypertension News, click here for Pulmonary Arterial Hypertension Ongoing Clinical Trial Analysis
Pulmonary Arterial Hypertension Emerging Drugs
Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).
Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment
There are approx. 55+ key companies which are developing the therapies for Pulmonary Arterial Hypertension. The companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Liquidia Technologies.
Find out more about the Pulmonary Arterial Hypertension Pipeline Segmentation, Therapeutics Assessment, and Pulmonary Arterial Hypertension Emerging Drugs @ Pulmonary Arterial Hypertension Treatment Landscape
Scope of the Pulmonary Arterial Hypertension Pipeline Report
Dive deep into rich insights for drugs for Pulmonary Arterial Hypertension Pipeline Companies and Therapies, click here @ Pulmonary Arterial Hypertension Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Pulmonary Arterial Hypertension Mergers and acquisitions, Pulmonary Arterial Hypertension Licensing Activities @ Pulmonary Arterial Hypertension Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/